Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
19. Mai 2022 17:00 ET
|
Radius Health Inc.; The Menarini Group
EMERALD study met both its primary end points of progression-free survival (PFS) in overall population and in ESR1 mutated patientsPFS rate at 12 months with elacestrant was 22.3% vs. 9.4% with SOC in...
Radius Health, Inc. First Quarter 2022 Results
05. Mai 2022 07:30 ET
|
Radius Health Inc.
Q1 2022 TYMLOS® product net revenue of $43 million vs. $45 million in Q1 2021° Q1 results: in-line with previously guided 1H 2022 company target of $97 million° Reiterating FY 2022 TYMLOS Net Revenue...
Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022
25. April 2022 08:30 ET
|
Radius Health Inc.
BOSTON, April 25, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that it will release its first quarter 2022 financial results on Thursday,...
Radius Provides Agenda for Today’s R&D Webcast
05. April 2022 08:00 ET
|
Radius Health Inc.
Focus: RAD011, an investigational synthetic cannabidiol oral solutionWebcast details: 10:00am to 12:00pm for current or prospective investors and sell side analystsObjectives: asset overview, science,...
Radius Health Announces Leadership Appointments
16. März 2022 08:30 ET
|
Radius Health Inc.
BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), today announced appointments to new roles on its executive leadership team, effective...
Radius Health Provides Business Update on Bone Health
08. März 2022 08:30 ET
|
Radius Health Inc.
Exclusive extension of research discovery collaboration with Mass General Hospital (MGH)Focus of the program: development of novel oral SIK inhibitors for musculoskeletal diseasesExtension of activity...
Wells Fargo Equity Research to Host Fireside Chat with Radius CEO
07. März 2022 08:30 ET
|
Radius Health Inc.
BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that Kelly Martin, CEO, has accepted an invitation to participate in a...
Radius to Host Neuroscience R&D Webcast April 5, 2022
03. März 2022 16:05 ET
|
Radius Health Inc.
Focus: RAD011, our investigational synthetic cannabidiol oral solutionBroad market interest in the underlying science, data, and clinical translation of the assetGoal: provide foundational review of...
Radius Health Files sNDA for TYMLOS® in Men with Osteoporosis
01. März 2022 08:00 ET
|
Radius Health Inc.
Filed sNDA with the FDA ahead of schedule on Friday, February 25, 2022Filing based on the positive ATOM study data previously announced on October 18, 2021There is a 10-month FDA review BOSTON, March...
Radius Health, Inc. Fourth Quarter & Full Year 2021 Results
24. Februar 2022 07:30 ET
|
Radius Health Inc.
Q4 2021 TYMLOS® net revenue of $65 million vs. $60 million in Q4 2020, up 9%This is a record quarter – over 18 quarters – since the launch in May 2017FY 2021 TYMLOS Net Revenue of $219 vs. $208...